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Supplementary Figure 1. Familial segregation analysis of PIH1D3 mutations 4 
Pedigrees of affected families are shown indicating the genotypes of affected boys (black squares), confirmed carrier 5 
females (filled circle), and wildtypes (white boxes and circles). Asterisk indicates situs inversus. In GVA30, carrier 6 
sibling II:3 has an affected son (ungenotyped). Probands arrowed. Sanger sequence of mutations are displayed with 7 
the mutation in red box and mutant amino acids in red lettering; note that in the GVA30 example, the reverse primer 8 
sequence has been used, but the forward sequence content and corresponding amino acids are shown at the bottom. 9 
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Supplementary Figure 2. Schematic representation of the interstitial deletions of the long arm of the X 17 
chromosome carried by affected individuals DCP855, DCP1337, DCP603 and DCP1747 18 
(a) Patients were genotyped with the HumanOmniExpress 24 BeadChip from Illumina and the data were analyzed 19 
with the Genome Studio and CNV partition 3.1.6 softwares (Illumina). Each blue dot represents one individual single-20 
nucleotide polymorphism (SNP). Each panel represents the log R ratio (red line), which is the log ratio of observed 21 
probe density to expected probe density. The log R ratio drop under 0 (pink area) indicates the loss of material.  22 
(b) SNPs located at the internal and external boundaries of the deletions (Grch37) are respectively in red and black. 23 
Red boxes show location of PIH1D3 at the distal boundary of the 1.93Mb deleted region shared by the four probands. 24 
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Supplementary Figure 3. Expression of mutant PIH1D3 proteins 28 
In vitro over-expression in HEK293 cells of GFP-tagged human PIH1D3 harbouring different disease-associated 29 
mutations.  The molecular weight (kDa) of the expressed protein was assessed by western blotting using anti-PIH1D3 30 
(right, top panel), anti-GFP (right, middle panel) or the loading control anti-GAPDH (right, bottom panel) antisera. 31 
PIH1D3 carrying the missense change D133Y did not migrate differently, but PIH1D3 carrying p.Glu43* and 32 
p.Ile164Leufs*11 were truncated as expected (p.Glu43* protein was only detected by GFP immunostaining since it 33 
lacks the domain containing the anti-PIH1D3 antigen, shown left). Uncropped data for the blots is shown in 34 
Supplementary Figure 14. 35 
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Supplementary Figure 4. PIH1D3 protein modelling and cross-species conservation 74 
(a) Primary structure of PIH1D3 annotated with Phyre-generated secondary structure and disorder, coloured to 75 
indicate strength of confidence of domain predictions. (b) Sequence alignment of representative homologues of 76 
PIH1D3 generated using T-Coffee (http://tcoffee.crg.cat/), illustrated with ESPript 3.0.3. The Phyre-predicted 77 
secondary structure of human PIH1D3 is shown above the alignment. Residues predicted with high confidence to be 78 
disordered are coloured cyan. D133 is highlighted in magenta.  79 
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Supplementary Figure 5. Eukaryote conservation of PIH1D3 orthologs across cilate species 82 
Scoring presence (black circle) or absence (white circle) of a PIH1D3 orthologue in species without cilia/flagella, with 83 
nonmotile cilia or with motile cilia/flagella. PIH1D3 is present in species with ODA and IDA, supporting a role in 84 
intraflagellar transport (IFT)-related dynein arm assembly. Akin to studies on another putative dynein assembly factor, 85 
LRRC56, PIH1D3 is absent from the moss Selaginella moellendorfii which shows secondary loss of ODAs (its male 86 
gametes have flagella only), and also the diatom Thalassiosira pseudonana that retains ODAs but does not require IFT 87 
for ciliary assembly.2 88 
 89 
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Supplementary Figure 6. Phylogenetic tree modelling of the evolutionary conservation of PIH1D3 92 
Phylogeny of all PIH1D3 orthologs from Ensembl, plus ciliate species of interest. The two mouse homologs of 93 
PIH1D3 on chromosome 1 and chromosome X are indicated. Phylogeny generated using PhyML using LG Model and 94 
nearest neighbour interchange topology optimisation.1 95 
 96 
 97 
Supplementary Figure 7. (Top) ESE prediction within PIH1D3 exon 3 by Human Splicing Finder V3.0 tool. 98 
(Bottom) The c.127G>T mutation disrupts the 3’ ESE of exon 3 (pink). The physiologic intron 3 acceptor splice site is 99 
weak (MaxEntScan score: 1.07). An intact exon 3 ESE is, therefore, probably crucial for proper splicing of this exon. 100 
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Supplementary Figure 8. RT-PCR of PIH1D3 transcripts from PCD12 II:1 nasal respiratory epithelial cells  106 
(a) Different sized products are amplified in reverse transcription PCR (RT-PCR) analysis of nasal respiratory 107 
epithelial cells of an unaffected control (471 bp) and individual PCD12 II:1 (315 bp) using primers in PIH1D3 exon 1 108 
and exon 6. The size difference of 156 bp between control and PCD12 II:1 cDNA products corresponds to the length 109 
of exon 3. These products were amplified after several attempts to optimize the reaction on limited amounts of patient 110 
material. M, molecular marker. (b) Sanger sequencing of the cDNA product amplified in the control showed the 111 
expected cDNA splice junction between exon 3 and exon 4 (top). The PCD12 II:1 patient cDNA product showed 112 
splicing between exon 1 and exon 4, indicating that exon 3 is absent (bottom). Notably, PIH1D3 transcripts amplified 113 
from respiratory cells in both control and patient did not contain exon 2 (belonging to the 5’UTR of PIH1D3), 114 
corresponding to NM_173494.1 in Figure 1 of the main paper.  115 
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Supplementary Figure 9. Expression of zebrafish pih1d3 during development 124 
Time course RT-PCR measuring full-length zebrafish pih1d3 mRNA expression in wild type TuAB embryos. 125 
Samples were collected at 4-cell stage (4C), 6-somite stage (6SS, approximately 12 hours post-fertilization (hpf)), 24 126 
hpf and 48 hpf. The non-ciliary e1fa mRNA serves as a loading control. NTC, no template control.  127 
 128 
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Supplementary Figure 10. Pronephric cyst phenotypes in zebrafish hi1392Tg mutants 131 
(a, b) Transmission electron microscopy at 72 hours post fertilization shows dilation of the pronephros in hi1392Tg 132 
mutants (b) and disruption of the usual tightly packed arrangement of motile cilia that is seen in controls siblings (ctl 133 
sib, a). Scale bar, 2 µm. Insets are higher magnification images of the indicated pronephric cilia. (c-f) Cross sections 134 
of hematoxylin and eosin-stained 50 hpf embryos show the dilated pronephric ducts and glomeruli of mutants (d, f) 135 
compared to control siblings (c, e). NC, notochord; glo, glomerulus. 136 
 137 
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Supplementary Figure 11. Rescue of hi1392Tg mutant phenotypes by injection of zebrafish pih1d3  140 
(a, b) Representative clutches of 72 hpf hi1392Tg mutant embryos injected at one-cell stage with 250 pg of zebrafish 141 
pih1d3 mRNA, showing rescue of mutant phenotypes (b) compared to non-injected siblings (a). (c) Quantification of 142 
common phenotypes in 48 hpf hi1392Tg mutant embryos (red columns) versus embryos injected with 250pg of 143 
zebrafish pih1d3 mRNA (green columns). There was complete or significant rescue of ventral body axis curvature, 144 
pronephric cysts and abnormal cardiac looping (images not shown). Columns represent data from 3 separate 145 
experiments with n=29-111 per experiment. Error bars show standard deviation, significance calculated using two way 146 
ANOVA, p value *<0.05, **<0.005, ***<0.001.  147 
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Supplementary Figure 12. Co-localisation of TGN-46 and PIH1D3 in HEK293 cells 157 
HEK293 transfected with GFP-tagged PIH1D3 (anti-GFP in red, Roche) shows co-localisation with endogenous 158 
TGN-46 (green, AbD Serotec). Nuclei in blue, DAPI. Scale bar, 10µM. 159 
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 164 
Supplementary Figure 13. Electron tomography of the 96nm repeat including the inner dynein arm of a 165 
healthy control  166 
(a) Axonemal structure from an averaged tomogram of the axoneme of a respiratory cilium, constructed from a nasal 167 
brushing a healthy male of 31yrs (similar age to PCD12 in main paper Figure 6). The image viewed in longitudinal 168 
section was coloured using Chimera software (a) and rotated to 90 degrees to view the microtubule doublet in 169 
transverse section (c). (b) A corresponding diagram of the 96nm repeating axoneme in longitudinal (left) and 170 
transverse (right) section. Outer dynein arms are depicted in blue, inner dynein arms in red and the dynein regulatory 171 
complex in yellow. All components are present in this healthy sample. The dashed white line represents the start of the 172 
equivalent diagram and tomogram in Figure 6 of the main paper, grey dashed line indicates the 96 nm span. 173 
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Supplementary Figure 14. Uncropped blots from manuscript 182 
(a) Uncropped blots from Supplementary Figure 3. (b) Uncropped blots from Figure 5, showing data for all of Figure 183 
5c, d. Extra bands cropped from the images are IgG antibody proteins present in the pulldown lanes. 184 
  185 
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Supplementary Table 1. Coding and non-coding elements within PIH1D3 X chromosome deletions Asterisk 186 
indicates only the last 6 coding exons of IL1RAPL2 are deleted. Indicated in bold are genes referenced in the OMIM 187 
database. 188 
189 
 DCP855 DC1337 DCP603 DCP1747 
Boundaries of the deletion 
(Grch37) 
103,077,143-
106,814,443 
103,580,266-
106,853,641 
104,582,944-
106,510,764 
104,582,944-
106,510,764 
Deleted genes RAB9B  
 RNA5SP511  
 ELF2P1  
 LOC644261  
 DPPA3P1  
 TMSB15B  
 H2BFXP  
 H2BFWT  
 H2BFM  
 LOC100101478  
 LOC101060236  
 SLC25A53  
 ZCCHC18  
 LOC286437  
 FAM199X  
 ESX1  
 PHBP10 PHBP10  
 RPL18AP14 RPL18AP14  
 TEX13A TEX13A  
 IL1RAPL2 IL1RAPL2 IL1RAPL2* IL1RAPL2* 
 KCTD9P2 KCTD9P2 KCTD9P2 KCTD9P2 
 RNU6-207P RNU6-207P RNU6-207P RNU6-207P 
 NRK NRK NRK NRK 
 SERPINA7 SERPINA7 SERPINA7 SERPINA7 
 LOC100131448 LOC100131448 LOC100131448 LOC100131448 
 MUM1L1 MUM1L1 MUM1L1 MUM1L1 
 LOC107178920 LOC107178920 LOC107178920 LOC107178920 
 NAP1L4P2 NAP1L4P2 NAP1L4P2 NAP1L4P2 
 SERPINA7P1 SERPINA7P1 SERPINA7P1 SERPINA7P1 
 CXorf57 CXorf57 CXorf57 CXorf57 
 MIR548AN MIR548AN MIR548AN MIR548AN 
 RNF128 RNF128 RNF128 RNF128 
 TBC1D8B TBC1D8B TBC1D8B TBC1D8B 
 RIPPLY1 RIPPLY1 RIPPLY1 RIPPLY1 
 CLDN2 CLDN2 CLDN2 CLDN2 
 MORC4 MORC4 MORC4 MORC4 
 EEF1A1P40 EEF1A1P40 EEF1A1P40 EEF1A1P40 
 RBM41 RBM41 RBM41 RBM41 
 NUP62CL NUP62CL NUP62CL NUP62CL 
 LOC644563 LOC644563 LOC644563 LOC644563 
 PIH1D3 PIH1D3 PIH1D3 PIH1D3 
 MYCLP1 MYCLP1  
 DNAJA1P3 DNAJA1P3  
 KRT18P49 KRT18P49  
 FRMPD3-AS1 FRMPD3-AS1  
 FRMPD3 FRMPD3  
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Supplementary Table 2. Clinical features of males carrying PIH1D3 mutations  190 
WES, whole exome sequencing. NGS, next-generation sequencing. SI, situs inversus. OM, otitis media. NO, nitric oxide. NRD, neonatal respiratory distress. NA, not 191 
assessed/available. NR, not relevant. FEV1, lung forced expiratory volume in 1 second measurement. IDA, ODA, inner dynein arm, outer dynein arm. 192 
 193 
Individual  
and 
Origin 
Genetic 
analysis 
method 
Genotype Age 
diagnosed 
SI Bronchiectasis Respiratory 
symptoms 
Other 
symptoms 
FEV1 
(date and 
age test 
performed) 
Fertility Otitis 
media 
and 
hearing 
Nasal 
NO 
High speed video 
microscopy 
Ultrastructural 
defect (TEM) 
PCD12 II:1 
UK 
WES c.127G>T  ; 
p.Glu43* 
2 yrs Yes Mild 
bronchiectasis 
Recurrent upper 
and lower 
respiratory tract 
infections. 
Bilateral sinusitis 
  FEV1 91% 
predicted 
(2013 at 27 
yrs old) 
Complete 
asthenozoospermia 
OM with 
effusion 
and 
hearing 
difficulties 
1999 7.5 
nL/min  
2009 0.5 
nL/min 
1989 – Static; 2009 - 
60% static, 40% 
beating with a 
normal frequency 
but jittery beat 
12.6Hz; 2015 – 
Mixed beat pattern, 
some static patches 
others disorganised 
beating 
1989 (4% total 
absence, 82% 
ODA retained); 
2009 (33% total 
absence, 58% 
ODA retained); 
2015 (38% total 
absence, 45% 
ODA retained, 
2% IDA 
retained) 
PCD392 
II:1 
Sri Lanka 
NGS gene 
panel 
c.266G>A ; 
p.Trp89* 
17 yrs No Bronchiectasis 
(bilateral lower 
lobes & middle 
lobe) 
Recurrent upper 
and lower 
respiratory tract 
infections. 
Sinusitis 
Asthma, 
dev delay 
FEV1 23% 
predicted 
(2015 at 25 
yrs old - 
difficulty 
with 
technique) 
NR No 
hearing 
issues  
2008 
40nL/min 
2008 Jan – Static 
0Hz; 2008 April – 
Static 0Hz 
2008 (14% total 
absence, 61% 
IDA retained); 
2008 (9% total 
absence, 82% 
IDA retained) 
DC121 
(DCP68) 
France 
Sanger 
sequencing 
c. 397G>T; 
p.Asp133Tyr 
4 yrs No Mild 
bronchiectasis 
Recurrent upper 
and lower 
respiratory tract 
infections 
  FEV1 89% 
predicted 
(2016 at 17 
yrs old) 
NR OM  NA 2000 Oct - Static 
0Hz;  2003 Jul - 
Static 0Hz   
 
GVA30 
II:1 
Spain 
WES c.489_492del; 
p.Ile164Leufs*11 
NA Yes Bilateral lower 
lobe 
bronchiectasis  
NRD. Upper 
respiratory tract 
infections since 
birth. Chronic 
rhinorrea and 
cough, recurrent 
pneumonia from 
very young age. 
Sinusitis 
Type II 
narcolepsy  
NA Complete 
asthenozoospermia 
OM with 
effusion 
and 
hearing 
difficulties 
NA Static (0Hz) 2016 (85% total 
absence, 6% 
ODA retained, 
9% IDA 
retained) 
GVA30 
II:2 
Spain 
WES c.489_492del; 
p.Ile164Leufs*11 
NA Yes Bilateral lower 
lobe 
bronchiectasis  
NRD. Upper 
respiratory tract 
infections since 
birth. Chronic 
rhinorrea and 
cough, recurrent 
pneumonia from 
very young age. 
Sinusitis 
Type II 
narcolepsy  
NA Complete 
asthenozoospermia 
OM with 
effusion 
and 
hearing 
difficulties 
NA Static (0Hz) NA 
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GVA30 
II:3 
Spain 
WES c.489_492del; 
p.Ile164Leufs*11 
NA Yes Bilateral lower 
lobe 
bronchiectasis  
NRD. Upper 
respiratory tract 
infections since 
birth. Chronic 
rhinorrea and 
cough, recurrent 
pneumonia from 
very young age. 
Sinusitis 
Type II 
narcolepsy  
NA Complete 
asthenozoospermia 
OM with 
effusion 
and 
hearing 
difficulties 
NA Static (0Hz) NA 
 DCP855  
(DC518) 
France 
SNP array 3.73-Mb deletion 6 yrs No Bronchiectasis NRD. Recurrent 
upper and lower 
respiratory tract 
infections 
Intellectual 
disability 
Unknown NR OM  NA 2011 Feb - Static 
0Hz (HSV) 
IDA+ODA (4 
biopsies: very 
few cilia, no 
quantification) 
 DCP1337 
(DC864) 
France 
Sanger 
sequencing, 
SNP array 
3.27-Mb deletion 9 yrs No Bronchiectasis 
(in middle 
lobe), 
lobectomy 
NRD. Recurrent 
upper and lower 
respiratory tract 
infections 
Transient 
mild 
cerebellar 
syndrome, 
delayed 
milestones 
FEV1 72% 
predicted 
(2015 at 12 
yrs old) 
NR OM  NA 2012 June - Static 
0Hz  
IDA+ODA 
(97% total 
absence; 3% 
retained ODA) 
 DCP603 
(DC393) 
Morocco 
SNP array 1.93-Mb deletion Birth Yes Bronchiectasis 
(in left and 
right lower 
lobes and 
middle lobe) 
NRD. Recurrent 
upper and lower 
respiratory tract 
infections 
  Obstruction 
and 
hypoxemia 
NR OM  7 nL/min 2001 Feb - Static 
0Hz;  2008 Sep - 
Static 0Hz   
IDA+ODA 
(100% total 
absence) 
 DCP1747 
(DC393) 
Morocco 
SNP array 1.93-Mb deletion 3 yrs No No 
bronchiectasis 
NRD. Recurrent 
upper and lower 
respiratory tract 
infections 
  FEV1 96% 
predicted 
(2014 at 5 
years old) 
NR OM, 
severe 
bilateral 
hearing 
loss  
NA 2012 March - Static 
0Hz  
IDA+ODA 
(93.5% total 
absence; 1.5% 
retained IDA; 
5% retained 
ODA) 
 DCP894 
(DC539) 
France 
Sanger 
sequencing 
c.263_268delinsG; 
p.Ile88Argfs*12 
29 yrs No Bronchiectasis Recurrent upper 
and lower 
respiratory tract 
infections 
 Unknown Asthenozoospermia OM  7 nL/min 2011 June - Static 
0Hz (HSV) 
IDA+ODA 
(97% total 
absence; 0.5% 
retained IDA;  
2.5% retained 
ODA) 
 DCP1218 
(DC768) 
France 
Sanger 
sequencing 
c.511C>T; 
p.Gln171* 
Birth Yes Mild 
bronchiectasis 
(in middle 
lobe) 
NRD. Recurrent 
upper and lower 
respiratory tract 
infections 
  FEV1 48% 
predicted 
(2016 at 13 
yrs old) 
NR OM  NA 2011 Sep - Static 
0Hz  
IDA+ODA 
(90% total 
absence; 3% 
retained IDA; 
7% retained 
ODA) 
 DCP1849 
(DC768) 
France 
Sanger 
sequencing 
c.511C>T; 
p.Gln171* 
Birth No No 
bronchiectasis 
NRD. Cough and 
rhinitis 
  NA NR OM  NA NA NA 
 194 
15 
 
 
Supplementary Table 3. Primers used in this study 195 
  196 
Gene    Primers 197 
Gateway 
PIH1D3 5’-CACCGAATCTGAAAATATGGATTCTGAA-3’       
 5’ TCAGAAGAAATTAGCAATATCTAA-3’ 
DNAI2 5’-CACCGAGATTGTGTACGTGTACGTC-3’  
 5’-CTAGGCTAAGTCTTCTTCCACTTC-3’
SD mutagenesis 
PIH1D3 (p.E43*) 5’-CTACTTAATCCTGAATAAGAGGATGATTCTG-3’ 
 5’-CAGAATCATCCTCTTATTCAGGATTAAGTAG-3’ 
PIH1D3 (p.W89*)  5’GGAAAATAATGAGGACATCTAGAATTCAGAAGAGATTCCAGA-3’ 
 5’-TCTGGAATCTCTTCTGAATTCTAGATGTCCTCATTATTTTCC-3’ 
PIH1D3 (p.D133Y) 5’-AGGGTTGTCAAAAAAGTACTCCTCAACAGGTTG-3’ 
 5’-CAACCTGTTGAGGAGTACTTTTTTGACAACCCT-3’
PIH1D3 
(p.T163_I164delfs) 
5’-AAATTGATATCCAGGAAACCTTGACCTTCGTACTCCTC-3’ 
5’-GAGGAGTACGAAGGTCAAGGTTTCCTGGATATCAATTT-3’ 
RT-qPCR in ciliogenesis 
PIH1D3 5’-GTTGTTGCAGTGAACTAGTGG-3’ 
 5’-TTATCAACAGCTTCTTCTGAGGAGT-3’ 
DNAI2                   5’-AAGGAGAAGGGTAAGGCGGA-3’                       
 5’-GACTTGGTTGCTGAGGCACT-3’ 
DNAH5 5’-TGCAGATGCCATGGTTCACT-3’ 
 5’-ATGAAGCCAACCTCGTCAGG-3’
GAPDH 5’-TGCACCACCAACTGCTTAGC-3’ 
 5’-GGCATGGACTGTGGTCATGAG-3’ 
Genomic PCR primers to Sanger sequence PIH1D3 (start at exon 3 because exons 1,2 are non-coding) 
PIH1D3 exon 3F 5’-TCCAGGTCTGTGAGTTAGCAAAA-3’ 
PIH1D3 exon 3R 5’-TCATGCATAATCAGCCTTGTAGC-3’ 
PIH1D3 exon 4F 5’-TCACTGAGCTGGAACTAGGGT-3’ 
PIH1D3 exon 4R 5’-ACCACACGTGACTTTCTTGGTC-3’ 
PIH1D3 exon 5F 5’-TGCATGGAAAAGATATCAAAGCGT-3’ 
PIH1D3 exon 5R 5’-AACTGAAAGGAAGGTGTTATGCTTT-3’ 
PIH1D3 exon 6F 5’-TATATGCCTGAAGACCTGCAAGC-3’ 
PIH1D3 exon 6R 5’-GGACGGAACTAGGATGGAAGAAA-3’ 
PIH1D3 exon 7F 5’-TTTGGAGCCAGAAACCTTAGTCA-3’ 
PIH1D3 exon 7R 5’-CCACTTTTCTTCAGACTTTAGGGG-3’ 
PIH1D3 exon 8F 5’-GCCTGTAAACATAGCCTGAGACT-3’ 
PIH1D3 exon 8R 5’-AAAGCACAACTGAAGAAGCCAAA-3’ 
RT-PCR in PCD12 
PIH1D3 exon 3F 5’-TTACAGCTCTGGAAGCCCT -3’ 
PIH1D3 exon 5R 5’-TTTCCTCGCTGGTTTCAGGG-3’ 
PIH1D3 exon 6R 5’-CTTCAGTTCCCACCTGCTGT-3’ 
Genomic primers for mutation confirmation and segregation  
PCD12 II:1 F 5’-ACAGCTCTGGAAGCCCTCTC-3’ 
PCD12 II:1 R 5’-AGCCTTGTAGCTTCCTGTGA-3’ 
PCD392 II:1F 5’-TGAACCCAAACTGAGTGTGAAGA-3’ 
PCD392 II:1R 5’-CAATTACACATGCCTTCCGTGT-3’ 
DCP68F 5’-TATATGCCTGAAGACCTGCAAGC-3’ 
DCP68R 5’-GGACGGAACTAGGATGGAAGAAA3’ 
GVA II:1 30F 5’- TGGAGCCAGAAACCTTAGTCA-3’ 
GVA II:1 30R 5’- ACCTTACAGCCCCACAAAATG-3’ 
DCP894F 5’-TGCATGGAAAAGATATCAAAGCGT-3’ 
DCP894F 5’-AACTGAAAGGAAGGTGTTATGCTTT-3’ 
16 
 
 
DCP1218/1849F 5’-TTTGGAGCCAGAAACCTTAGTCA-3’ 
DCP1218/1849F 5’-CCACTTTTCTTCAGACTTTAGGGG-3’ 
DCP855F NA* (Large multi-gene deletion including PIH1D3) 
DCP855F NA* (Large multi-gene deletion including PIH1D3) 
DCP1337F NA* (Large multi-gene deletion including PIH1D3) 
DCP1337F NA* (Large multi-gene deletion including PIH1D3) 
DCP603/1747F NA* (Large multi-gene deletion including PIH1D3) 
DCP603/1747F NA* (Large multi-gene deletion including PIH1D3) 
*: not applicable, large multigene deletion characterised using SNP arrays. 198 
 199 
Supplementary Table 4. Primary antibodies used in this study 200 
 201 
Antigen Antibody Host Species Source Application 
GM130 35/GM130 IgG1, Mouse BD Transduction IF (1:100) 
TGN46 AHP 500 IgG, Sheep AbD Serotec IF (1:500) 
GFP 7.1 and 13.1 IgG1, Mouse Roche co-IP (1µg), WB 
(1:1000-1500) 
MYC 9E10 Mouse Merck Millipore WB (1:3000) 
GAPDH 6C5 Mouse Merck Millipore WB (1:500)
 202 
Supplementary Table 5. Secondary antibodies used in this study 203 
 204 
Antigen Host 
Species 
Source Application 
Alexa 488, 594 – conjugated 
anti rabbit IgG (H+L) 
Goat Invitrogen (Molecular Probes) IF (1:1000) 
Alexa 488, 594 – conjugated 
anti mouse IgG1 
Goat Invitrogen (Molecular Probes) IF (1:1000) 
Alexa 488, 594 -  conjugated 
anti mouse IgG2b 
Goat Invitrogen (Molecular Probes) IF (1:1000) 
Alexa 488 – conjugated anti 
mouse IgG (H+L) 
Donkey Invitrogen (Molecular Probes) IF (1:1000) 
Alexa 488 – conjugated anti 
sheep IgG (H+L) 
Donkey Invitrogen (Molecular Probes) IF (1:1000) 
ECL α-Mouse IgG, HRP-
conjugated 
Sheep GE Healthcare UK Ltd WB (1:3000) 
ECL α-Rabbit IgG, HRP-
conjugated 
Donkey GE Healthcare UK Ltd WB (1:3000) 
 205 
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